NCT03171610View on ClinicalTrials.gov

Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy

NACompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

January 3, 2018

Study Completion Date

January 3, 2018

Conditions
Patients Undergoing Laparoscopic Nephrectomy
Interventions
DRUG

Sufentanil group

PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.

DRUG

Fentanyl group

PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.

Trial Locations (1)

03722

Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03171610 - Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy | Biotech Hunter | Biotech Hunter